We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
OGT Launch Cancer Sequencing Panel at ACGS
Product News

OGT Launch Cancer Sequencing Panel at ACGS

OGT Launch Cancer Sequencing Panel at ACGS
Product News

OGT Launch Cancer Sequencing Panel at ACGS


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "OGT Launch Cancer Sequencing Panel at ACGS"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford Gene Technology will launch its new SureSeq™ Solid Tumour Panel at the Association for Clinical Genetic Science (ACGS) meeting at Birmingham UK, on the 29-30th April. Fully validated on formalin-fixed, paraffin-embedded (FFPE) samples, the new 60-gene next generation sequencing (NGS) hybridisation-based enrichment panel offers researchers accurate and reliable solid tumour profiling for both known and novel variants.

The content of the panel has been defined by recognised cancer experts, covering key genes for a range of cancer types including breast, prostate, ovarian, lung and colorectal. All exons of these genes are fully covered, including mutation hotspots, enabling both detection and discovery of known and novel variants respectively.

The hybridisation-based SureSeq Solid Tumour Panel minimises PCR bias and duplications commonly associated with alternative enrichment methodologies, enabling greater run-to-run consistency. This is particularly important in situations where there is limited sample or where the ability to detect minor allele frequencies is required, such as in heterogeneous tumour samples. Such sample types require a highly uniform and sensitive enrichment and OGT’s expert bait design ensures this by providing efficient and improved uniformity of coverage of the targeted regions, enabling all variants to be called with maximum confidence.

Providing easy access to meaningful data, the SureSeq Solid Tumour Panel comes with OGT’s unique Variant Analysis Report, equipping researchers with the freedom to explore and retrospectively interrogate data with additional or new selection criteria, without the need for additional in-house bioinformatics resource. Using the report, data can be easily filtered by numerous parameters, including gene, depth of coverage, somatic variants and predicted effect on the protein. In addition, all variants are fully annotated with links to various databases.

Delegates of the ACGS meeting can find out more about the new panel in a talk by Dr Matthew Smith (West Midlands Regional Genetics Laboratory) titled “Developing a 60 gene somatic cancer capture panel for consolidated tumour profiling” at 12.20pm on 30th April  2014.

Advertisement